a~tivated.5 Activated platelets increase expres-
SIOn of a receptor protein termed GPIIblIIa which vi.a fibrin~gen binding supports strong homotypic adhesion and the formation of a platelet plug.s Coagulation Exposed subendothelial tissues express tissue fa~tor (TF), a 45 kDa integral membrane protem, as do damaged endothelial cells.? When TF bin?s to~ctivated factor VII in the presence of calcium, It enhances the factor VII induced activation of factor X over lOoo-fold and hence strongly ac~ivates. the final common pathway of coagulation ( Figure 1 ). This is the extrinsic pathway of coagulation which can be monitored in the.taboratory by the prothrombin time (PT). Negatively charged subendothelial surfaces are als? exposed by endothelial damage and these can activate factor XII which via a series of reactions generates a complex of activated factors VIII and IX. This complex in the presence of calcium and a phospholipid surface will activate factor X. This is the intrinsic pathway of coagulation which can be monitored by the activated partial thromboplastin tiI?e (A~TT). Activated factor X when complexed With activated factor V on a phospholipid surface in the presence of calcium generates active thrombin from prothrombin releasing the activation fragment 1.2. Thrombin converts fibrinogen to fibrin monomer releasing fibrinopeptides A and B. Fibrin monomer polymerizes and forms stable clot when cross-linked by activated factor XIII. This represents the final common pathway of coagulation which requires adequate amounts of fibrinogen ( Figure 1 ).
Fibrinolysis
Plasmin generated from plasminogen can degrade cross-linked fibrin releasing fibrin radation products (FDPs). Plasmin generation can occur via factor XII or kallikrein but the physiological activators are tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively) ( Figure 2 ). The activity of the PAs is greatly enhanced when bound to fibrin which serves to localize fibrinolysis to formed clot.
Control of haemostasis
Whilst haemostasis is essential to repair vascular damage, the vasculature must be maintained as a flowing circuit and several mechanisms prevent inappropriate activation of the above systems.
• Tissue factor expression on exposed subendothelium and damaged endothelial cells localizes activated factor X generation to the damaged area." • The phospholipid required for activity of the VIIIa-IXa and Xa-Va complexes can be provided by the platelet membrane localizing fibrin deposition to adherent platelets on the subendothelium.? • Several natural anticoagulant proteins exist to control fibrin deposition ( Figure 3 ): -Damaged endothelial cells and platelets release a 32 kDa protein termed tissue factor pathway inhibitor (TFPI) which potently inhibits the TF-VIIa complex and Xa. This serves to restrict the amount of Xa generated by localized endothelial damage. 10 -Antithrombin III (ATill) is a glycoprotein synthesized by the liver which can bind to endothelial cell associated proteoglycan and inactivate thrombin or Xa. ll -Thrombomodulin is another integral membrane protein expressed by endothelial cells which can bind free thrombin and accelerate its inactivation.P The thrombin-thrombomodulin complex binds and activates a further vitamin K dependent protein termed protein C. n Activated PC together with a cofactor termed protein S can inactivate Va and VIIIa. 14 ATIII and activated protein C inhibit surface-bound factors poorly, providing a further mechanism to localize fibrin generation to damaged vasculature with adherent platelets. Thrombin released in the circulation away from such areas will bind to endothelial thrombomodulin or proteoglycans and hence be inactivated by ATIII.
-Free plasmin is rapidly inactivated in the circulation by the protease inhibitor (Xz-antiplasmin, although inhibition of fibrin bound plasmin by this mechanism is 10-1oo-fold slower.P Fibrinolysis is therefore localized to stable clot. The generation of plasmin is limited by the rapid removal of circulating tPA by the Iiver I 6 and the release from endothelial cells of a 50 kDa protein termed plasminogen activator inhibitor 1 (PAl-1) which inhibits both tPA and uPA,17 It is clear from Figure 3 that the endo-II NTRINSIC PATHWAY I Disseminated intravascular coagulation 185 thelium plays a key role in orchestrating appropriate haemostasis to areas of damaged vasculature.
Initiating events in ole
The events which control the normal haemostatic response break down in the context of DIC, leading to uncontrolled fibrin deposition and fibrinolysis with consumption of coagulation factors and the relevant inhibitors. Several descriptive terms can be applied to this process:
Coagulation pathways. Shaded boxes represent natural anticoagulant mechanisms. Abbreviations: TM, thrombomodulin; PL, phospholipid; HMWK, high molecular weight kininogen; TF, tissue factor; TFPI, tissue factor pathway inhibitor.
• Acute uncompensated DIC refers to overwhelming activation of the haemostatic mechanism with failure to compensate for factor consumption, resulting in depletion of coagulation factors, inhibitors and often platelets. This may be associated with a severe bleeding diathesis. • Chronic compensated DIC occurs when activation of the haemostatic mechanism consumes factors, but increased production of the relevant factors and inhibitors prevents their depletion. This may be an asymptomatic laboratory finding. .
Several mechanisms may be responsible for overwhelming the homeostatic factors which localize the activation of coagulation: 1) Tissue factor (TF) expression. TF has a widespread tissue distribution but is normally separated from the coagulation mechanisms in the circulation by the endothelial cell barrier. 18 Widespread trauma such as crush injury or burns will expose the circulation to large amounts ofTF. The brain is rich in TF and similarly head injury with brain trauma will expose the circulation to large amounts of TF. The uterine contents in pregnancy are a potent source of TF and obstetric events such as abruption, amniotic fluid embolus
or uterine rupture will expose large quantities of TF. The presence of such large quantities of TF will overwhelm the ability of TFPI to restrict the amount of Xa generated by the extrinsic pathway and may be an important initiating event in the pathogenesis of DIC.8 Endothelial cells do not normally express TF, but physical insult, sepsis or toxins can induce TF expression.tv-w The same systemic stimuli can induce macrophages to express TF.21-23 Widespread vascular damage or sepsis can therefore expose the circulation to large amounts of TF and can be further initiating events for DIC. Some malignancies express large amounts of TF which may contribute to DIC. 24 2) Proteolytic enzyme activity. The presence of increased proteolytic enzyme activity from endogenous or exogenous sources can overwhelm the natural anticoagulant mechanisms and initiate DIC. Endogenous proteases are released by pancreatitis or intravascular leucocyte activation with the release of elastase and other enzymes.P Similarly, myeloid malignancies can release intracellular proteases and if the leukaemic cell burden is large this can initiate DIC.25 Exogenous proteases are introduced by the bites or stings of venomous animals, particularly snakes and spiders.w
3) Endothelial cell function. As seen above, the endothelium elaborates factors which restrict the haemostatic response. These include prostacyclin and endothelium-derived relaxation factor, now characterized as nitric oxide, which inhibit platelet aggregations? together with TFPI, thrombomodulin, proteins and PAI-l which have been discussed. Widespread endothelial damage by trauma, toxins, sepsis or vascular disease can therefore result in continued plate-
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let activation and non-localized fibrin generation hence DIC. 4) Liver synthetic function and bone marrow reserve. The ability to compensate for the above initiating events will depend upon the ability to replace consumed factors and inhibitors. Since the relevant factors are synthesized by the liver, the above initiating events will be more likely to provoke DIC in the context of hepatic impairment. state. The same stimuli release von Willebrand factor-" and platelet activating factors? (PAF) from endothelium which will stimulate platelet aggregation. Enhanced thrombin generation from this sequence of events further augments these procoagulant effects on the endothelium and platelets. [38] [39] [40] Stimulated endothelium releases IL-8, a potent chemotaxin for neutrophils (PMN) and monocytes." IL-8 and TNF result in endothelial expression of adhesion molecules such as selectins (GMP-140 or endothelial leucocyte adhesion molecule, ELAM.l)42,43 or intercellular adhesion molecules (ICAM-l, ICAM-2).44 These arrest PMN and monocytes on activated endothelium where PAF, complement components and bacteria can cause intravascular activation of these cells. Ac~ivated PMN can release proteolytic enzymes which cause unregulated fibrin deposition.s> They also release reactive oxygen species which are toxic to the endothelium-e and by oxidising key amino acids can inactivate protease inhibitors''? and thrombomodulin.ss Activated monocytes express TF, release factors VNIl and can bind and activate factor X.49 These mechanisms are procoagulant and provoke endothelial damage to further fuel the process. These interactions may be of prime importance in the pathogenesis of DIC. Evidence to support this can be seen in the generalized Schwarzman reaction which is a fatal response to LPS injections in laboratory animals; after an initial 'priming' dose, a second exposure results in death from organ thrombosis with multiorgan failure and DIC. Animals leucodepleted before the second injection are spared and do not develop intravascular fibrin deposition, but passive infusion of leucocytes with the second LPS injection restores the full fatal reaction.s" It has also been recently reported in an in vitro animal model that the prevention of leucocyte adhesion to adherent platelets blocks fibrin deposition within thrombus.>! The FOPs generated by enhanced fibrinolysis impair further fibrin polymerization, and soluble small fibrin polymers are detectable in the circulation. Hepatic impairment will also result in reduced clearance of FOPs, activated clotting factors and plasminogen activators so further impairing the generation of stable fibrin clot. These factors together with thrombocytopenia and coagulation factor depletion can result in a severe haemostatic defect. · The pathogenesis of DIC is clearly multifactonal and the relative importance of particular factors in a given case may be relevant in the development of new therapeutic strategies.
Laboratory diagnosis of DIC
A clinical suspicion of DIC is raised by the presence of generalized oozing from venepuncture or vascular access sites, local haemorrhages, petechiae or thrombotic episodes in association with underlying clinical disorders known to provoke coagulopathy. Of the laboratory tests routinely used to assess coagulation, no single test will confirm the presence of DIC. The screening tests outlined in Table 2 will provide evidence of factor depletion, secondary fibrinolysis and platelet consumption. This, together with a clinical assessment, should suffice to confirm the presence of DIC. In specialist centres more sophisticated tests of coagulation can be used to confirm the diagnosis.
Screening tests
The PT, APTT and thrombin time will be prolonged by factor depletion, hypofibrinogenaemia and the presence of elevated FDPs.52 Fibrinogen levels can be measured and will usually confirm depletion, but it should be remembered that fibrinogen is an acute phase reactant hence depletion in severely ill patients may simply return levels back into the normal laboratory range. Elevated levels of FOPs are found in DIC but are not specific: elevated levels occur in renal or hepatic failure as a result of reduced clearance; dysfibrinogenaemia elevates FOP levels and heparin or rheumatoid factors give false positive assay results. Moreover, elevated FOPs can result from either fibrinolysis or fibrinogenolysis. A specific degradation product of fibrin, the D-dimer, is released only from cross-linked fibrin and elevated levels are, therefore, a more specific indicator of DIC53 although elevated levels can be found in localized deep venous thrombosis. The blood count will often reveal thrombocytopenia and examination of the blood film may show red cell fragmentation. 54
Specialist tests
These are not usually available in general Disseminated intravascular coagulation 189 haematology laboratories and are not necessary for routine clinical investigation and management. 1) Factor depletion. Specific assays of factors V, VII, X and prothrombin will show low levels together with elevated levels of fragment 1.2 released during the conversion of prothrombin to thrombin.P Complexes of inactivated factors bound to inhibitors will be raised. 55. 56 2) Inhibitor depletion. Assays specific for ATIII, protein C, protein Sand TFPI all show low levels in active DIC. 57-59
3) Enhanced fibrinolysis. Plasminogen and Q2antiplasmin levels fall in proportion with the severity of DIC. 60 Levels of fibrinopeptide A reflect thrombin activitye! and specific fragments can be measured which indicate the activity of plasmin on fibrin or fibrinogen.s-Whilst the screening tests should suggest DIC, the specialized tests can be useful in distinguishing other forms of coagulopathy from DIC. For example, infection can provoke functional vitamin K deficiency with prolonged coagulation times and induce thrombocytopenia, but in the absence of DIC levels of ATIII, Q2-antiplasmin and D-dimers should be normal. In the microangiopathies such as thromb?ti~thrombocytopenic purpura, thromb.ocytopem~IS present with red cell frag-mentatIon but neither enhanced fibrinolysis nor factor depletion is a feature. Liver failure can mimic DIC closely with decreased clotting factor and inhibitor synthesis, enhanced fibrinolysis, elevated FOPs and thrombocytopenia. Serial tests of coagulation, with progressive rise in FOP levels may provide the only means to confirm the presence of DIC, though it should be remembered that, in the presence of fibrinogen depletion, FOP levels may fall in spite of ongoing Ole. The Q2-antiplasmin level and thrombocytopenia may predict the risk of bleeding.63
Specific clinical associations with DIC

Infection
The role of LPS in the pathogenesis of DIC induced by Gram-negative bacterial infection has already been discussed. Infection with many other agents has also been described to cause DIC, and cytokine generation may also be a significant factor together with direct endothelial cell damage.
A specific syndrome termed purpura fulminans is associated with overwhelming sepsis and is associated with skin necrosis and digital gangrene due to vascular occlusion.
Malignancy
Coagulation abnormalities are found in up to 50% of patients with malignancy, and 10-15% of these develop clinically significant DIC.64 Cells from lymphomas, leukaemias, adenocarcinomas and sarcomas express TF,65 whilst those from adenocarcinomas and leukaemias release enzymes capable of activating factor X. 66 Expression of PA has been associated with metastatic potential in a number of solid tumours and may contribute to activation of fibrinolysis.s? Hepatic synthesis of ATIll and protein C is also reduced in metastatic malignancy, and these patients may be prone to thrombosis. 64 ,68 A specific coagulopathy is associated with the acute promyelocytic myeloid leukaemia (APML); these cells express TF, factor X activating proteases, tPA and release IL-t. Coagulation tests are prolonged in APML with hypofibrinogenaemia and elevated FOPs which together with thrombocytopenia result in considerable mortality from haemorrhage. Levels of protein C and ATIll are usually normal in APML patients, hence it is unclear if the coagulopathy results from DIC or primary hyperfibrinolysis.s? The latter has recently been proposed to be associated with uP A release.
Shock
Hypotension, anoxia and acidosis from whatever cause are associated with endothelial cell damage, cytokine release and intravascular leucocyte activation. Together with TF exposure it is not surprising that trauma, burns, massive transfusion and tissue infarction may all be accompanied by DIC. The adult respiratory distress syndrome (ARDS) often follows these events and DIC has been described in up to 20% of such patients.70 As many as 50% of ARDS patients have pulmonary vascular thrombosis at autopsy and it remains unclear whether the coagulopathy is a primary causal or a secondary event.71
Envenomation
Snake and spider bites are associated with DIC. The venoms involved contain factors which cause tissue necrosis with TF exposure, damage endothelial cells and induce vasodilation or haemolysis, and proteolytic enzymes which directly activate thrombin or degrade fibrin. Vipers and rattlesnakes are particularly potent inducers of DIC. 26 
Obstetric complications
In normal pregnancy coagulation factor levels increase together with PAl, but PA and protein S levels fall, resulting in a prothrombotic tendency.P In obstetric emergencies which expose the circulation to the TF-rich uterine contents, fulminant acute DIC ensues but rapidly responds to delivery of the fetus. Coagulation in pregnancy may be further complicated by pregnancy-induced hypertension where hepatic impairment, endothelial damage, red cell fragmentation and platelet activation can occur.
Management
The mortality of acute DIC is high but usually results from progression of the underlying disorders rather than from haemostatic abnormalities. The management of DIC can be divided into general measures and specific therapies.
General measures
Identifying initiating factors
DIC is unlikely to resolve unless the initiating stimuli can be identified and removed. Sepsis should be sought and aggressively treated. Specific therapy should be given if available; for example, antivenoms should be administered if the offending species responsible for envenomation can be identified. In the case of obstetric emergencies, plans should be made for delivery of the fetus.
Circulatory support
The maintenance of normal tissue perfusion is essential to prevent renal or hepatic impairment and endothelial cell damage by anoxia or acidosis. Keeping the haematocrit above 35% helps to maintain tissue oxygenation and prevents the impairment of platelet function associated with anaemia.
Nutrition
The consumption of coagulation factors and platelets requires compensatory responses from the liver and bone marrow. Adequate levels of vitamin K and folic acid are required for these responses and should be maintained.P
Advice
It is reasonable to inform local haematology staff to coordinate the assessment of laboratory tests and enable adequate provision to be made for the availability of blood products.
Specific therapy
Blood product support Recent 
Heparin therapy
Trials have not conclusively demonstrated a reduction in mortality in patients with DIC treated with heparin. Its use is therefore controversial, but it carries the risk of provoking haemorrhage and hence cannot be advocated for general use in Ole. Some studies have suggested benefit in specific syndromes associated with DIC: purpura fulminans, acute promyelocytic leukaemia (APML) and chronic DIC associated with malignancy or intrauterine fetal death have all been reported to be improved by small doses (5-10 U/kg/hr) of intravenous heparin. 6 9-78 Many of these studies are of poor design with small patient numbers, making interpretation difficult. A recent large study of APML demonstrated no difference in haemorrhagic deaths for patients given supportive blood product therapy in the presence or absence of prophylactic heparin therapy."?
Antifibrino/ytic therapy
Tranexamic acid and e-aminocaproic acid bind to lysine residues on fibrin or fibrinogen and prevent the action of plasmin. Whilst this will diminish fibrinolysis it may exacerbate thrombosis and their general use in DIC cannot be advocated. Trials have suggested some efficacy in combination with low-dose heparin therapy in DIC associated with APML or peritoneovenous shunts for chronic ascites. 69 ,80 Antithrombin III concentrate This product ameliorates DIC in animal models and limited use in humans indicates its potential benefit. 8 1 -83 A large trial is awaited but one limitation of its use may be an inability to inhibit surface-bound thrombin or Xa.
New approaches
A better understanding of the pathophysiological processes which can generate DIC has suggested novel therapeutic approaches which have been reported to have efficacy is animal models but for which clinical data are awaited.
1) Protease inhibitors. Aprotinin is in inhibi-
tor initially reported to be of benefit in pancreatitis but which attenuates the coagulopathy and mortality of LPS administration to pigs. 84 A natural variant of the elastase inhibitor ucantitrypsin termed Ut-ATPittsburgh has broad anti protease activity. Large amounts of this natural variant have been synthesized by recombinant technology and it inhibits thrombin, kallikren, XIa and XIIa. This product attenuates the DIC and mortality associated with Pseudomonas infection in pigs.85 2) Thrombomodulin.
Recombinant human thrombomodulin attenuates LPS-induced coagulopathy in rats. 86 Since TNF downregulates thrombomodulin during the pathogenesis of DIC, the monoclonal antibody against TNF which has been developed for use in sepsis could be of benefit in DIC. 87 3) Tissue factor pathway inhibitor (TPFl). Since this natural inhibitor prevents activation of Xa via TF and levels are depleted in acute DIC, a rationale for its use in DIC is obvious. Recombinant human TFPI has been demonstrated to ameliorate TF-induced DIC in rabbits.s" DIC is a potentially lethal complication of events which disturb the normal homeostatic mechanisms of the haemostatic response. Its recognition and prompt appropriate management are of paramount importance for a successful clinical outcome. This review has attempted to provide insight into the clinical relevance of the pathophysiology and the rational use of therapeutic strategies based upon the available diagnostic tests.
